Momentum Multi-Asset Value Trust plc (the “Company”)
Publication of Residual Net Asset Value per Share
In connection with the circular posted on 21 July 2023 (the “Circular”), the Board of the Company is pleased to announce that the Residual Net Asset Value per Share was 145.86 pence, as at 11.59 p.m. on 17 August 2023 (the “Calculation Date”).
Subject to the passing of the resolution at the Second General Meeting, Shareholders that have elected (or are deemed to have elected) for the Cash Option are expected to receive approximately 145 pence (rounded down to the nearest whole penny) per Ordinary Share with “B” rights. In accordance with the Scheme, cheques are expected to be dispatched in respect of the Cash
Option and CREST payments made to Shareholders that have elected (or are deemed to have elected) for the Cash Option not later than 10 Business Days after the Effective Date.
A further announcement is expected to be made later this week concerning Shareholders that have elected (or are deemed to have elected) for the Rollover Option, detailing the number of ICVC Shares that they will receive for every Ordinary Share with “A” rights held. Subject to the passing of the resolution at the Second General Meeting, the ICVC Shares are expected to be issued on 23 August 2023. The ICVC Shares are being issued on the basis detailed in Part 2 of the Circular, with the value of the ICVC Rollover Pool being calculated at 12.00 noon on the Effective Date of 23 August 2023 (calculated in accordance with the valuation policies and procedures of the ICVC, as described in the ICVC Prospectus).
Capitalised terms used in this announcement have the meanings given to them in
the Circular.
Back to All News
All Market News
Other Market News
GSK plc Overall Survival Data for Blenrep
Games Workshop Group plc Announces Agreement With Amazon
Prudential Considers Minority Sale in Eastspring Investments
James Cropper Announces Collaboration with Oxford University
GSK plc Blenrep Combination China Filing Acceptance
GSK plc Nucala COPD Submission Accepted by FDA
Sign up for our Stock News Highlights
Delivered to your inbox every Friday